Devimistat: all 32 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin LymphomaTerminatedNCT04217317Phase 2Results posted
- Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)TerminatedNCT04203160Phase 1/2Results posted
- Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the PancreasCompletedNCT03504423Phase 3Results posted
- Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AMLTerminatedNCT03504410Phase 3Results posted
- CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic SarcomaCompletedNCT02484391Phase 1Results posted
- CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous TherapyTerminatedNCT01902381Phase 2Results posted
- CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By SurgeryCompletedNCT01766219Phase 1/2Results posted
- Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic CancerWithdrawnNCT06518538Phase 2
- Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the PancreasWithdrawnNCT05926206Phase 1/2
- CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)WithdrawnNCT05854966Phase 2
- CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic AdenocarcinomaTerminatedNCT05325281Phase 1
- CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal CancerWithdrawnNCT05070104Phase 1
- To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft TissueCompletedNCT04593758Phase 1/2
- CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic SyndromeWithdrawnNCT03929211Phase 1/2
- A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk TranslocationsCompletedNCT03793140Phase 2
- CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic CancerCompletedNCT03699319Phase 1/2
- CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic CancerWithdrawnNCT03374852Phase 2
- CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung CancerWithdrawnNCT03370159Phase 1/2
- 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaWithdrawnNCT02472626Phase 1/2
- CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by SurgeryCompletedNCT02232152Phase 1
- CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
- CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT02168140Phase 1
- CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung CancerCompletedNCT01931787Phase 1
- CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT01839981Phase 1
- CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic CancerCompletedNCT01835041Phase 1
- Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer PatientsTerminatedNCT01832857Phase 2
- Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic CancerWithdrawnNCT01830322Phase 2
- CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01768897Phase 1
- Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic SyndromeWithdrawnNCT01520805Phase 2
- Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic MalignanciesCompletedNCT01034475Phase 1
- A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer PatientsTerminatedNCT00907166Phase 1/2
- A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced MalignanciesCompletedNCT00741403Phase 1